DRDR MCI Onehealth Technologies Inc

MCI Onehealth Technologies Inc. ("MCI") (TSX: DRDR), a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, is pleased to provide news of a recently demonstrated positive impact on patient care from use of the technology platform provided by Khure Health, an MCI wholly-owned subsidiary that provides AI-powered clinical intelligence technology and services to physicians to support earlier diagnosis of rare diseases and now also chronic conditions.

Khure Health’s clinical intelligence platform now supports physicians with over 110 rare and chronic disease-specific AI algorithms designed to help physicians save precious time and identify patients with potential risk of these complex diseases earlier in their disease progression to help physicians end their suffering and save lives.

Khure Health is pleased to announce its first peer-reviewed publication in The Canadian Journal of Kidney Health and Disease. “Impacting management of chronic kidney disease through primary care practice audits: A quality improvement study” by authors A. Mosa, D Watts, and N. Tangri.1

The paper summarizes the use of Khure’s technology to compliantly screen 361,299 primary care electronic medical records, across 201 Ontario practices, which led to the identification of 8,194 patients with Stage 3 Chronic Kidney Disease at risk for progression or cardiovascular events. From these at-risk patients, 2,010 individuals (10 patients per practice) at high or moderate risk were selected by the physician for a chart audit via Khure Health’s clinical platform. Physicians then made clinical decisions regarding appropriate additional testing or prescription of disease-modifying therapy, which occurred in 24% of these patients. The paper concludes that an AI-enabled EHR clinical decision support application can enable improved laboratory testing and management.

“Khure Health’s mission is to help physicians identify rare, complex and chronic diseases earlier in their disease progression to end suffering and save lives. This paper demonstrates the validity of the Khure platform as much-needed support for overburdened doctors, helping them immediately optimize the care of their patients at risk of rare, complex and chronic disease,” said Don Watts, President of Khure. “The patients who received care pathway changes from their physician as a result of the support our technology provided, may now have a better chance to slow their disease progression and perhaps not need dialysis or a kidney transplant in the future.”

“We are very proud to be helping physicians make such a measurable impact for their patients. Early diagnosis and preventive care, through the use of advanced technology to support physicians, can not only help to support improved quality of life for patients, but if broadly deployed, can also help to save significant health system costs. We’re excited to be rapidly scaling the deployment of Khure Health’s clinical intelligence platform to primary care physicians and specialists across Canada and internationally,” said Dr. Alexander Dobranowski, MCI Onehealth CEO. “Khure’s success is a key factor fueling MCI’s accelerating growth in higher-margin, data-driven and clinical research initiatives that have direct benefit for patients.”

About Khure Health

Khure Health has grown its business helping primary care physicians and specialists identify potential rare, complex and chronic disease patient risk within their practices. Khure’s AI-enabled clinical intelligence platform allows healthcare practitioners to utilize the vast amounts of valuable clinical data sitting idle in their electronic health records to help identify potential opportunities to improve patient care and create healthcare system efficiencies for all stakeholders. By partnering with global pharmaceutical companies and patient advocacy groups, Khure Health develops advanced clinical algorithms to identify patients with potential risk or in need of care pathway optimization. Its cloud-based platform allows Khure to scale rapidly and to enter new geographic markets efficiently, as it recently did in entering the US market. Khure’s, privacy regulation-compliant technology is also helping to accelerate clinical research and scientific discovery.

About MCI

MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with approximately 280 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. MCI provides data insights as a service in six categories: rare disease; complex major medical/chronic; patient cohort building; clinical trial recruitment; synthetic health data and bespoke insights. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap. For more information, visit mcionehealth.com.

Citation

1.

Mosa AI, Watts D, Tangri N. Impacting Management of Chronic Kidney Disease Through Primary Care Practice Audits: A Quality Improvement Study. Canadian Journal of Kidney Health and Disease. 2022;9. doi:10.1177/20543581221144840

For media enquiries please contact:

Nolan Reeds | nolan@mcionehealth.com

Certain statements in this press release, constitute “forward-looking information” and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements include statements with respect to the potential for growth of MCI and its subsidiary, Khure Health, and the expected benefits and other impacts of Khure Health’s platform to physicians, patients and other parties. The words “increase”, “continue”, “enable”, “to help”, “to assist”, “potential”, “impact”, “improve”, “grow”, “empower”, “optimize”, “extend”, “save”, “expand”, or variations of such words and phrases or statements that certain future conditions, actions, events or results such as “will”, “may”, “could”, “would”, “should”, “might” or “can”, or negative versions thereof, and other similar expressions, identify forward-looking statements. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by MCI as of the date of such statements, are outside of MCI's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: MCI and Khure’s ability to maintain and grow their relationships with data-insight customers, clinics, physicians and specialists; their ability to maintain and grow their technology and research relationships and collaborations; the potential benefits of their technology and research relationships and collaborations; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth; sufficiency of current working capital to support future operating and working capital requirements; the stability of general economic and market conditions; currency exchange rates and interest rates; the ability of MCI and its subsidiaries to comply with applicable laws and regulations; MCI and its subsidiaries’ continued compliance with third party intellectual property rights; the anticipated effects of COVID-19; and that the risk factors noted below, collectively, do not have a material impact on MCI's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.

Known and unknown risk factors, many of which are beyond the control of MCI, could cause the actual results of MCI to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in MCI's annual information form dated March 31, 2022, which is available under MCI's SEDAR profile at www.sedar.com. The risk factors are not intended to represent a complete list of the factors that could affect MCI and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. MCI disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.